EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

FEED-Cystic Fibrosis (FEED-CF)

Not Applicable

Recruiting

Conditions: Cystic Fibrosis
Cystic Fibrosis-related Diabetes

Interventions: Other: High-added sugar, high-fat CF diet
Other: Low-added sugar, high-fat diet

First Posted Date: 2023-03-13

Last Posted Date: 2024-06-13

Lead Sponsor: Emory University

Target Recruit Count: 60

Registration Number: NCT05766774

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2

Recruiting

Conditions: Malignant Ureter Neoplasm
Stage III Bladder Cancer AJCC v8
Urachal Adenocarcinoma
Malignant Urethral Neoplasm
Metastatic Bladder Carcinoma
Locally Advanced Bladder Carcinoma
Malignant Renal Pelvis Neoplasm
Unresectable Bladder Carcinoma
Bladder Squamous Cell Carcinoma
Stage IV Bladder Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Enfortumab Vedotin
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Other: Questionnaire Administration

First Posted Date: 2023-03-06

Last Posted Date: 2024-06-10

Lead Sponsor: Emory University

Target Recruit Count: 25

Registration Number: NCT05756569

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations

MDMA Plus Exposure Therapy for PTSD

Phase 2

Recruiting

Conditions: PTSD

Interventions: Drug: MDMA

First Posted Date: 2023-02-27

Last Posted Date: 2024-05-16

Lead Sponsor: Emory University

Target Recruit Count: 40

Registration Number: NCT05746572

Locations: 🇺🇸
Emory Brain Health Center, Atlanta, Georgia, United States

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

Phase 4

Recruiting

Conditions: Non-cystic Fibrosis Bronchiectasis

Interventions: Drug: Trikafta

First Posted Date: 2023-02-24

Last Posted Date: 2024-07-09

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT05743946

Locations: 🇺🇸
The Emory Clinic, Atlanta, Georgia, United States

Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

Not Applicable

Completed

Conditions: End Stage Kidney Disease

Interventions: Device: Continuous glucose monitoring (CGM)

First Posted Date: 2023-02-23

Last Posted Date: 2024-04-05

Lead Sponsor: Emory University

Target Recruit Count: 40

Registration Number: NCT05741489

Locations: 🇺🇸
Emory Dialysis at Northside, Atlanta, Georgia, United States
🇺🇸
Emory Dialysis at Greenbriar, Atlanta, Georgia, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

and more 1 locations

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1

Recruiting

Conditions: Castration-Sensitive Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: Abiraterone
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Enzalutamide
Procedure: FDG-Positron Emission Tomography
Drug: Docetaxel
Procedure: Magnetic Resonance Imaging
Procedure: PSMA PET Scan
Drug: Vudalimab

First Posted Date: 2023-02-17

Last Posted Date: 2023-08-21

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT05733351

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment

Not Applicable

Recruiting

Conditions: Opioid Use
Opioid Abuse

Interventions: Behavioral: Sociobehavioral Intervention

First Posted Date: 2023-02-02

Last Posted Date: 2024-10-01

Lead Sponsor: Emory University

Target Recruit Count: 480

Registration Number: NCT05711056

Locations: 🇺🇸
Georgia Poison Center, Atlanta, Georgia, United States

A Web-Based Dyadic Intervention for Colorectal Cancer

Not Applicable

Recruiting

Conditions: Colorectal Carcinoma

Interventions: Other: Internet-Based Intervention
Other: Interview
Other: Survey Administration
Other: Electronic Health Record Review

First Posted Date: 2022-12-23

Last Posted Date: 2024-12-10

Lead Sponsor: Emory University

Target Recruit Count: 56

Registration Number: NCT05663203

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

Sugammadex as Rescue Therapy

Phase 4

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Placebo
Drug: Sugammadex

First Posted Date: 2022-12-22

Last Posted Date: 2024-08-16

Lead Sponsor: Emory University

Target Recruit Count: 71

Registration Number: NCT05661409

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

Enhancing the A in SAFE for Trachoma

Phase 4

Completed

Conditions: Trachoma

Interventions: Drug: Azithromycin for Routine Community-wide MDA
Drug: Two Additional Rounds of Azithromycin for Children
Drug: Azithromycin for Second Community-wide MDA

First Posted Date: 2022-12-02

Last Posted Date: 2024-02-29

Lead Sponsor: Emory University

Target Recruit Count: 34630

Registration Number: NCT05634759

Locations: 🇸🇸
Ministry of Health Republic of South Sudan, Juba, South Sudan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy